Loading
Nerve Injury and Regeneration / Hereditary Neurological Disorders · Journal article
Cancers · July 11, 2026
Raises a question worth testing. It does not answer one.
This preclinical study develops a transgenic mouse model expressing Cre-inducible Rabl6a to investigate the functional role of RABL6A in MPNST. In DhhCre; Rabl6a-tg mice with CRISPR-induced MPNST, elevated Rabl6a expression accelerated tumor progression and increased tumor angiogenesis without affecting tumor initiation, suggesting RABL6A acts as a driver of established disease. The model establishes a tool for further investigation of RABL6A's role in sarcoma biology but does not directly translate to human clinical outcomes or therapeutic strategy.
Preclinical transgenic mouse model with CRISPR-induced tumors. Double transgenic DhhCre; Rabl6a-tg mice engineered for Schwann-cell-specific Rabl6a expression; comparison cohort was DhhCre control mice without transgenic Rabl6a. No human subjects.. Intervention: Cre-inducible transgenic Rabl6a expression in Schwann cells; CRISPR-mediated editing of Nf1, Ink4a, and Arf in sciatic nerve.. Compared with: DhhCre control mice without transgenic Rabl6a, also subjected to CRISPR Nf1, Ink4a, Arf editing..
Increased Rabl6a expression in DhhCre; Rabl6a-tg mice significantly accelerated tumor progression relative to DhhCre control mice Rabl6a phenotype was associated with increased tumor angiogenesis but not proliferation Elevated Rabl6a had no effect on de novo MPNST initiation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This model provides a preclinical tool for mechanistic investigation of RABL6A's role in MPNST progression but is not sufficiently mature to inform clinical decision-making or drug development strategy without further validation and translation studies.
This is a mechanistic, preclinical mouse model study demonstrating RABL6A's functional role in sarcoma progression using transgenic mice and CRISPR-induced tumors, without clinical outcome data or translation to human disease.
As stated by the source record.
This model provides a preclinical tool for mechanistic investigation of RABL6A's role in MPNST progression but is not sufficiently mature to inform clinical decision-making or drug development strategy without further validation and translation studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are deadly sarcomas that arise from Schwann cells and lack effective therapies. RABL6A is an oncogenic Rab-like GTPase whose expression is associated with worse survival in many human cancers. It is required for human MPNST cell survival, and its expression is dramatically increased in patient MPNSTs compared to benign precursor lesions. Methods: To model elevated expression of RABL6A in vivo, we developed transgenic mice expressing Cre-inducible Rabl6a. These Rabl6a-tg mice express the murine Rabl6a cDNA with a 5′ hemagglutinin [HA] epitope sequence downstream of a CMV enhancer and separated by a lox–stop–lox cassette. Double transgenic DhhCre; Rabl6a-tg mice were generated to achieve Schwann-cell specific Cre expression from the Desert hedgehog (Dhh) promoter. De novo MPNSTs were induced by CRISPR editing of Nf1, Ink4a, and Arf genes in the mouse sciatic nerve. Results: Cre-dependent expression of transgenic Rabl6a was verified at the mRNA and protein levels in Cre-positive mouse embryo fibroblasts and tissues. Increased Rabl6a expression in DhhCre; Rabl6a-tg mice had no effect on de novo MPNST initiation but significantly accelerated tumor progression relative to DhhCre control mice. The Rabl6a phenotype was associated with increased tumor angiogenesis but not proliferation. Interestingly, many MPNSTs in the DhhCre background exhibited varying levels of rhabdomyoblastic (RMB) features. That immature muscle cell phenotype is a hallmark of malignant Triton tumors, a rare histological variant of human MPNSTs associated with worse outcomes. Conclusions: These data provide direct evidence that Rabl6a is a functional driver of MPNSTs while establishing Rabl6a-tg mice as a suitable model for investigating Rabl6a’s role in other lethal RABL6A-high tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.